Tags

Type your tag names separated by a space and hit enter

Oocyte vitrification as an efficient option for elective fertility preservation.
Fertil Steril. 2016 Mar; 105(3):755-764.e8.FS

Abstract

OBJECTIVE

To provide a detailed description of the current oocyte vitrification status as a means of elective fertility preservation (EFP).

DESIGN

Retrospective observational multicenter study.

SETTING

Private university-affiliated center.

PATIENT(S)

A total of 1,468 women who underwent EFP because of age or having associated a medical condition other than cancer (January 2007 to April 2015).

INTERVENTION(S)

None.

MAIN OUTCOME MEASURE(S)

Survival and cumulative live birth rate (CLBR) per consumed oocyte.

RESULT(S)

Mean age was higher with EFP due to age versus having an associated medical reason (37.7 y [95% confidence interval (CI) 36.5-37.9] vs. 35.7 y [95% CI 34.9-36.3]). In total, 137 patients (9.3%) returned to use their oocytes. Overall survival rate was 85.2% (95% CI 83.2-87.2). Live birth rate per patient was higher in women ≤35 years old than ≥36 years old (50% [95% CI 32.7-67.3] vs. 22.9% [95% CI 14.9-30.9]). CLBR was higher and increased faster in younger women. The gain in CLBR was sharp from 5 (15.4%, 95% CI -4.2 to 35.0) to 8 oocytes (40.8%, 95% CI 13.2-68.4), with an 8.4% gain per additional oocyte, in the ≤35-year-old group. The increase was slower with 10-15 oocytes, reaching a plateau CLBR of 85.2%. A milder increase (4.9% gain) was observed in the ≥36-year-old group (from 5.1% [95% CI -0.6 to 10.7] to 19.9% [95% CI 8.7-31.1] when 5-8 oocytes were consumed), reaching the plateau with 11 oocytes (CLBR 35.6%). Forty babies were born.

CONCLUSION(S)

At least 8-10 metaphase II oocytes are necessary to achieve reasonable success. Numbers should be individualized in women >36 years old. We suggest encouraging women who are motivated exclusively by a desire to postpone childbearing because of age, to come at younger ages to increase success possibilities.

Authors+Show Affiliations

IVI-Valencia, Institut Universitari IVI, Valencia, Spain. Electronic address: ana.cobo@ivi.es.IVI-Madrid, Universidad Rey Juan Carlos, Madrid, Spain.IVI-Valencia, Institut Universitari IVI, Valencia, Spain.IVI-Las Palmas, Las Palmas, Spain.IVI Foundation, Hospital Universitari i Politècnic La Fe, Valencia, Spain.IVI-Valencia, Institut Universitari IVI, Valencia, Spain.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study

Language

eng

PubMed ID

26688429

Citation

Cobo, Ana, et al. "Oocyte Vitrification as an Efficient Option for Elective Fertility Preservation." Fertility and Sterility, vol. 105, no. 3, 2016, pp. 755-764.e8.
Cobo A, García-Velasco JA, Coello A, et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755-764.e8.
Cobo, A., García-Velasco, J. A., Coello, A., Domingo, J., Pellicer, A., & Remohí, J. (2016). Oocyte vitrification as an efficient option for elective fertility preservation. Fertility and Sterility, 105(3), 755-e8. https://doi.org/10.1016/j.fertnstert.2015.11.027
Cobo A, et al. Oocyte Vitrification as an Efficient Option for Elective Fertility Preservation. Fertil Steril. 2016;105(3):755-764.e8. PubMed PMID: 26688429.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oocyte vitrification as an efficient option for elective fertility preservation. AU - Cobo,Ana, AU - García-Velasco,Juan A, AU - Coello,Aila, AU - Domingo,Javier, AU - Pellicer,Antonio, AU - Remohí,José, Y1 - 2015/12/10/ PY - 2015/09/21/received PY - 2015/11/03/revised PY - 2015/11/17/accepted PY - 2015/12/22/entrez PY - 2015/12/22/pubmed PY - 2016/7/20/medline KW - Fertility preservation KW - live birth KW - oocyte vitrification KW - survival rate SP - 755 EP - 764.e8 JF - Fertility and sterility JO - Fertil. Steril. VL - 105 IS - 3 N2 - OBJECTIVE: To provide a detailed description of the current oocyte vitrification status as a means of elective fertility preservation (EFP). DESIGN: Retrospective observational multicenter study. SETTING: Private university-affiliated center. PATIENT(S): A total of 1,468 women who underwent EFP because of age or having associated a medical condition other than cancer (January 2007 to April 2015). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Survival and cumulative live birth rate (CLBR) per consumed oocyte. RESULT(S): Mean age was higher with EFP due to age versus having an associated medical reason (37.7 y [95% confidence interval (CI) 36.5-37.9] vs. 35.7 y [95% CI 34.9-36.3]). In total, 137 patients (9.3%) returned to use their oocytes. Overall survival rate was 85.2% (95% CI 83.2-87.2). Live birth rate per patient was higher in women ≤35 years old than ≥36 years old (50% [95% CI 32.7-67.3] vs. 22.9% [95% CI 14.9-30.9]). CLBR was higher and increased faster in younger women. The gain in CLBR was sharp from 5 (15.4%, 95% CI -4.2 to 35.0) to 8 oocytes (40.8%, 95% CI 13.2-68.4), with an 8.4% gain per additional oocyte, in the ≤35-year-old group. The increase was slower with 10-15 oocytes, reaching a plateau CLBR of 85.2%. A milder increase (4.9% gain) was observed in the ≥36-year-old group (from 5.1% [95% CI -0.6 to 10.7] to 19.9% [95% CI 8.7-31.1] when 5-8 oocytes were consumed), reaching the plateau with 11 oocytes (CLBR 35.6%). Forty babies were born. CONCLUSION(S): At least 8-10 metaphase II oocytes are necessary to achieve reasonable success. Numbers should be individualized in women >36 years old. We suggest encouraging women who are motivated exclusively by a desire to postpone childbearing because of age, to come at younger ages to increase success possibilities. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/26688429/Oocyte_vitrification_as_an_efficient_option_for_elective_fertility_preservation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(15)02111-1 DB - PRIME DP - Unbound Medicine ER -